<p>CURRICULUM VITAE</p><p>Name Dr. Aditya Shirish Adhav</p><p>Address Adhav Hospital, Shivajinagar, Opp. Inox theatre, Nashik 422006</p><p>Phone number 0253-2414959</p><p>Mobile number +919860376209</p><p>Email address [email protected]</p><p>Date of birth 15/08/1987</p><p>Languages known English, Marathi and Hindi</p><p>Educational details:-</p><p>Graduation MBBS 2005-2010(NDMVPS Medical College and Hospital, Nashik) Recognised by Medical Council of India</p><p>Internship from Feb. 2010 to Feb. 2011(NDMVPS Medical College and Hospital, Nashik) Post Graduation PDVVPF’s Medical College, Ahmednagar (1st June 2011- 31stMay2014) under Maharashtra University of Health Sciences. Recognised by Medical Council of India Topic of Dissertation: - CLINICO-PATHOLOGICAL STUDY OF NON NEOPLASTIC AND NEOPLASTIC LESIONS OF BREAST WITH RADIOLOGICAL CORRELATION.</p><p>Senior resident SMBT Hospital Nasik 18thDec 2014 to 28th Jan 2015</p><p>Bharati Vidyapeeth Deemed University, Pune 2nd March 2015 to 30th June 2015.</p><p>Fellowship Breast surgery at Manavata Curie Cancer Centre, Nashik affiliated with Maharashtra University of Health Sciences from 2nd July 2015 to 31st Aug 2016.</p><p>Achievements: -</p><p>Academics Title Year Univers Institute Marks Remarks ity M.S MUHS, PDVVPF’s Medical 61% 1st Attempt General Nashik College, Surgery Ahmednagar MBBS 1st MUHS, NDMVPS Medical 1st Attempt 60% Nashik College 2nd MUHS, NDMVPS Medical 1st Attempt 64% Nashik College 3rd part I MUHS NDMVPS Medical 1st Attempt 61% Nashik College 3rd part II MUHS NDMVPS Medical 1st Attempt 62% Nashik College</p><p>Paper Presentation</p><p> Male Breast Lesions: A Scenario at our institute</p><p>Poster Presentation</p><p> Benign Multicystic Peritoneal Mesothelioma  Aesthetics in Breast Surgery  Rare But There: Male Breast Cancer</p><p>Publications in Indexed Journal</p><p> Benign Multicystic Peritoneal Mesothelioma  Amyand’s Hernia A Rare Sliding Hernia  Rare But There: Male Breast Cancer.</p><p> Intracystic Papillary Carcinoma Of Breast: A Case Report.</p><p> Anterior Mediastinal Mass: A Case Report Of Thymoma With Myasthenia Gravis.  Kikuchi Fujimoto Disease: A Rare Benign Disease.</p><p>Conferences Attended</p><p>1. Attended MASICON 2012 in Pune. 2. Poster presentation “Benign Multicystic Peritoneal Mesothelioma” in Nashik MASICON 2013. 3. Attended ASICON at Ahmedabad in 2013. 4. Paper presentation “Male Breast Lesions: A Scenario at our institute” at MASICON 2014.</p><p>5. Organised and attended Live Operative workshop and Multidisciplinary CME on Breast Surgery at Curie Manavata Cancer Centre Nashik October 2015. </p><p>6. Attended Current trends in Oncology Breast Chapter - 2016 at Ruby Hall Clinic, Pune. PRINCIPAL INVESTIGATOR IN</p><p>1) A Randomised double-blind study in two parts Part A – Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B – Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquemous non-small cell lung cancer (NSCLC).</p><p>2) A Randomized, Double-Blind, Multi- Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Paclitaxel Administered as First-Line Treatment in Patients with HER2 -Positive Metastatic Breast Cancer. 3) A Randomized, Open Label, Two Period, Single Dose, Crossover, Bioavailability Study Of Paclitaxel Injection Concentrate For Nano- Dispersion (PICN) And Abraxane® In Subjects With Locally Recurrent Or Metastatic Breast Cancer</p><p>SUB INVESTIGATOR IN 1) Prospective, multi-centric, randomized open-label, twoarm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR- 033 / Erbitux ® in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.</p><p>2) A Prospective, Randomized, Multi- Centre Study to Compare the Safety, Tolerability, and Efficacy Bevacizumab (Zydus Cadila) With Bevacizumab (Avastin ®) in Non-Small Cell Lung Cancer (NSCLC).</p><p>3) A Randomized,Double-blind,Placebo- controlled study to Evaluate the Long- term Safety and Efficacy of Darbepoetin Alpha Administered at 500mg once- Every-3- weeks in Anemic Subjects with Advanced Stage Non-small cell Lung Cancer Receiving Multi- cycle Chemotherapy.</p><p>4) A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Inta Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non - Small Cell Lung Cancer.</p>